The DOI matches its Crossref record; 88 of the 88 references it cites were found in a registry or an index.
Modern antipsychotic drugs: a critical overview
Open accessAbstract
Conventional antipsychotic drugs, used for a half century to treat a range of major psychiatric disorders, are being replaced in clinical practice by modern "atypical" antipsychotics, including aripiprazole, clozapine, olanzapine, quetiapine, risperidone and ziprasidone among others. As a class, the newer drugs have been promoted as being broadly clinically superior, but the evidence for this is problematic. In this brief critical overview, we consider the pharmacology, therapeutic effectiveness, tolerability, adverse effects and costs of individual modern agents versus older antipsychotic drugs. Because of typically minor differences between agents in clinical effectiveness and tolerability, and because of growing concerns about potential adverse long-term health consequences of some modern agents, it is reasonable to consider both older and newer drugs for clinical use, and it is important to inform patients of relative benefits, risks and costs of specific choices.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Goodman and Gilman's the Pharmacological Basis of Therapeutics
Stigelman, W. H., & Pharm, D. (1986) · Military Medicine · doi:10.1093/milmed/151.1.386 · Cited by 6,782
Clozapine for the Treatment-Resistant Schizophrenic: A Double-blind Comparison With Chlorpromazine
Kane, J. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800330013001 · Cited by 4,156
What are the functional consequences of neurocognitive deficits in schizophrenia?
(1996) · American Journal of Psychiatry · doi:10.1176/ajp.153.3.321 · Cited by 3,516
Psychopharmacology: The Fourth Generation of Progress
Bloom, F. E., & Kupfer, D. J. (1995) · Medical Entomology and Zoology · Cited by 2,985
Antipsychotic-induced weight gain: a comprehensive research synthesis
Allison, D. B., Mentore, J. L., Heo, M., Chandler, L. P., Cappelleri, J. C., Infante, M. C., & Weiden, P. J. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.11.1686 · Cited by 2,382
Discovering the Neural Basis of Human Social Anxiety: A Diagnostic and Therapeutic Imperative
Charney, D. S. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.1.1 · Cited by 1,428
Farde, L. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820070032005 · Cited by 1,419
Meltzer, H. Y. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.1.82 · Cited by 1,393
Schotte, A., Janssen, P. F. M., Gommeren, W., Luyten, W. H. M. L., Van Gompel, P., Lesage, A. S., De Loore, K., & Leysen, J. E. (1996) · Psychopharmacology · doi:10.1007/bf02245606 · Cited by 1,167
Kapur, S., & Seeman, P. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.3.360 · Cited by 1,140
Cited by
International Consensus Study of Antipsychotic Dosing
Gardner, D. M., Murphy, A. L., O'Donnell, H., Centorrino, F., & Baldessarini, R. J. (2010) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2009.09060802 · Cited by 1,301
Self-citationIncidence, risk factors and consequences of ICU delirium
Ouimet, S., Kavanagh, B. P., Gottfried, S. B., & Skrobik, Y. (2007) · Intensive Care Medicine · doi:10.1007/s00134-006-0399-8 · Cited by 972
The Anxiolytic Effects of Exercise: A Meta-Analysis of Randomized Trials and Dose–Response Analysis
Wipfli, B. M., Rethorst, C. D., & Landers, D. M. (2008) · Journal of Sport and Exercise Psychology · doi:10.1123/jsep.30.4.392 · Cited by 480
Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug
Zuardi, A. W., Crippa, J. A. S., Hallak, J. E. C., Moreira, F. A., & Guimarães, F. S. (2006) · Brazilian Journal of Medical and Biological Research · doi:10.1590/s0100-879x2006000400001 · Cited by 402
Drug-Induced Urinary Retention: Incidence, Management and Prevention
Verhamme, K. M. C., Sturkenboom, M. C. J. M., Stricker, B. H. C., & Bosch, R. (2008) · Drug Safety · doi:10.2165/00002018-200831050-00002 · Cited by 264
Neuronal defects in a human cellular model of 22q11.2 deletion syndrome
Khan, T. A., Revah, O., Gordon, A., Yoon, S.-J., Krawisz, A. K., Goold, C., Sun, Y., Kim, C. H., Tian, Y., Li, M.-Y., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-1043-9 · Cited by 186
The Intellectual Crisis of Psychiatric Research
Fava, G. A. (2006) · Psychotherapy and Psychosomatics · doi:10.1159/000092890 · Cited by 79
“from the massive amount of propaganda delivered by medical journals and meetings?The place of atypical antipsychotics in clinical practice is a good exemplification of this problem. Even though current evidence suggests to consider both older and newer drugs, because of growing concerns about potential adverse long-te…”
BackgroundPediatric Delirium: Evaluation, Management, and Special Considerations
Malas, N., Brahmbhatt, K., McDermott, C., Smith, A., Ortiz-Aguayo, R., & Turkel, S. (2017) · Current Psychiatry Reports · doi:10.1007/s11920-017-0817-3 · Cited by 67
Preclinical Behavioral Models for Predicting Antipsychotic Activity
Castagné, V., Moser, P. C., & Porsolt, R. D. (2009) · Advances in Pharmacology · doi:10.1016/s1054-3589(08)57010-4 · Cited by 64
Impact of Antipsychotics and Anticholinergics on Autonomic Modulation in Patients With Schizophrenia
Huang, W.-L., Chang, L.-R., Kuo, T. B. J., Lin, Y.-H., Chen, Y.-Z., & Yang, C. C. H. (2013) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3182839052 · Cited by 46
Evolution of neuroleptic-induced extrapyramidal syndromes under long-term neuroleptic treatment.
Modestin, J., Wehrli, M. V., Stephan, P. L., & Agarwalla, P. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2007.10.018 · Cited by 38
Metadata
- Authors
- Gardner, D. M.
- Venue
- Canadian Medical Association Journal
- Publisher
- CMA Joule Inc.
- Published
- 2005-06-21
- Volume
- 172
- Issue
- 13
- Pages
- 1703-1711
- ISSN
- 0820-3946 (ISSN-L)
- 1488-2329
- OpenAlex
- W2097648013
- Cited by
- 422
- References
- 88
- FWCI
- 21.63
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.